Scholarlink

Introduction <p>Transient viremia can occur in people with human immunodeficiency virus (HIV), often referred to as people with HIV (PWH), and is sometimes related to poor adherence to antiretroviral therapy (ART). Guidelines recommend achieving virologic resuppression with existing ART regimens while addressing the reasons for the lack of virologic control. However, there are limited clinical trial data on the effectiveness of the strategy of continuing the same ART regimen in treatment-experienced PWH following a period of viremia. This was a post hoc pooled analysis of eight clinical studies in PWH receiving bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF).</p> Methods <p>Viremic events occurring in participants receiving B/F/TAF were defined as ≥ 1 viral load (VL) measurement of ≥ 50&#xa0;copies/mL after virologic suppression (VL &lt; 50 copies/mL). Outcomes after viremic events were categorized as: virologic resuppression (≥ 1 subsequent VL &lt; 50 copies/mL); continued viremia (all subsequent VLs ≥ 50 copies/mL); or not evaluable (no subsequent VL assessment). Adherence was calculated by pill count from returned pill bottles.</p> Results <p>The analysis included 2801 participants. A total of 411 viremic events were experienced by 290 participants, 50% of whom were treatment&#xa0;naïve at B/F/TAF initiation, and the other 50% were virologically suppressed. A total of 91 participants experienced ≥ 1 viremic event of ≥ 1000&#xa0;copies/mL. The proportion of viremic events followed by resuppression on B/F/TAF was 90.3%, rising to 96.6% when nonevaluable data were excluded. The median (quartile [Q]1, Q3) time from a viremic event to documented resuppression was 22 (18, 36) days. Among 13 participants with continued viremia, 11 (84.6%) prematurely discontinued B/F/TAF. No treatment-emergent resistance was observed in participants with continued viremia. A significantly higher proportion of participants with a viremic event had &lt; 85% adherence compared with those without (10.0% and 4.2%, respectively; <i>p</i> = 0.0003).</p> Conclusions <p>Most participants receiving B/F/TAF experienced no viremic events. The vast majority of viremic events resolved with B/F/TAF continuation, without the need for treatment change.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) After A Viremic Event: A Pooled Analysis of Studies in People with HIV

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月15日

查看全文
  • Anton Pozniak,
  • Chloe Orkin,
  • Yazdan Yazdanpanah,
  • Axel Baumgarten,
  • Karam Mounzer,
  • Michelle L. D’Antoni,
  • Hailin Huang,
  • Hui Liu,
  • Kristen Andreatta,
  • Laurie A. VanderVeen,
  • Christian Callebaut,
  • Jason T. Hindman,
  • José R. Arribas

摘要

Introduction

Transient viremia can occur in people with human immunodeficiency virus (HIV), often referred to as people with HIV (PWH), and is sometimes related to poor adherence to antiretroviral therapy (ART). Guidelines recommend achieving virologic resuppression with existing ART regimens while addressing the reasons for the lack of virologic control. However, there are limited clinical trial data on the effectiveness of the strategy of continuing the same ART regimen in treatment-experienced PWH following a period of viremia. This was a post hoc pooled analysis of eight clinical studies in PWH receiving bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF).

Methods

Viremic events occurring in participants receiving B/F/TAF were defined as ≥ 1 viral load (VL) measurement of ≥ 50 copies/mL after virologic suppression (VL < 50 copies/mL). Outcomes after viremic events were categorized as: virologic resuppression (≥ 1 subsequent VL < 50 copies/mL); continued viremia (all subsequent VLs ≥ 50 copies/mL); or not evaluable (no subsequent VL assessment). Adherence was calculated by pill count from returned pill bottles.

Results

The analysis included 2801 participants. A total of 411 viremic events were experienced by 290 participants, 50% of whom were treatment naïve at B/F/TAF initiation, and the other 50% were virologically suppressed. A total of 91 participants experienced ≥ 1 viremic event of ≥ 1000 copies/mL. The proportion of viremic events followed by resuppression on B/F/TAF was 90.3%, rising to 96.6% when nonevaluable data were excluded. The median (quartile [Q]1, Q3) time from a viremic event to documented resuppression was 22 (18, 36) days. Among 13 participants with continued viremia, 11 (84.6%) prematurely discontinued B/F/TAF. No treatment-emergent resistance was observed in participants with continued viremia. A significantly higher proportion of participants with a viremic event had < 85% adherence compared with those without (10.0% and 4.2%, respectively; p = 0.0003).

Conclusions

Most participants receiving B/F/TAF experienced no viremic events. The vast majority of viremic events resolved with B/F/TAF continuation, without the need for treatment change.